Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 5 years
- Director since
- 2023
5 years of board service in total across 2 boards, counting each seat separately. Longest: Agios Pharmaceuticals Inc., 3 years.
Chief executive roles
Outstanding · grade A+
Out of 100, from shareholder return, dividends, growth and acquisitions.
Partial: only 20% of the scoring weight is on file.
- Revenue growth 20%
- 100
21.5% a year in revenue
20% of the scoring weight is on file. Figures cover December 2023 – December 2025.
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Agios Pharmaceuticals Inc. June 20, 202489.2%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 18, 2026 | Agios Pharmaceuticals Inc. | Option exercise | +2,816 | — | — |
| Jun 13, 2026 | Agios Pharmaceuticals Inc. | Option exercise | +1,976 | — | — |
| Mar 25, 2026 | ACADIA Pharmaceuticals Inc. | Open-market sale | −11,641 | $21.47 | $249,932 |
| Mar 24, 2026 | ACADIA Pharmaceuticals Inc. | Option exercise | +23,509 | — | — |
| Jun 20, 2025 | Agios Pharmaceuticals Inc. | Option exercise | +2,120 | — | — |
| Jun 13, 2025 | Agios Pharmaceuticals Inc. | Option exercise | +1,977 | — | — |
| Jun 13, 2024 | Agios Pharmaceuticals Inc. | Option exercise | +1,976 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.